Key Highlights

  • CVRx shares closed down 60% at $2.39.
  • Second-quarter 2026 Revenue rose 16% to $15.7 million.
  • U.S. Barostim sales rose 21%, with gross Margin expanding to 87%.
  • Weak Q3 guidance of $13.5-$14.5 million, below $14.7 million a year earlier, weighed on shares.

CVRx ( Nasdaq : CVRX) shares closed down 60% at $2.39 despite the company announcing that second-quarter 2026 revenue rose 16% to $15.7 million, with U.S. Barostim sales up 21% and gross margin expanding to 87%.

What Happened

Weak Q3 guidance of $13.5 million to $14.5 million, versus $14.7 million a year earlier, and continued cash burn weighed heavily on shares, despite reimbursement progress from Humana, CPT codes, and CMS IDE coverage.

The implied sequential and year-over-year revenue decline in the Q3 outlook stands in contrast to the 16% growth reported for the second quarter, a shift that appears to have significantly unsettled investors heading into the back half of the year.

Market Reaction

Shares plunged sharply as investors focused on the guided year-over-year revenue decline implied by the Q3 outlook and ongoing cash burn concerns, overshadowing the Q2 growth and margin expansion.

For a medical device company still working to expand adoption of Barostim, cash burn concerns tend to carry outsized weight with investors, since sustained losses raise the prospect of future dilutive financing if the commercial ramp does not accelerate.

Outlook

Continued reimbursement progress, alongside the trajectory of actual Q3 results relative to the weak guidance, is likely to remain the key Factor shaping sentiment toward CVRx's stock going forward.